Manganese-based metal-organic frameworks augment postoperative immunotherapy of high-intensity focused ultrasound

  • J Colloid Interface Sci. 2026 Apr 15:708:139847. doi: 10.1016/j.jcis.2026.139847.
Xinchang Huang  1 ,  Xirui Luo  1 ,  Tong Su  2 ,  Kunli Su  2 ,  Song Peng  2 ,  Huanan Li  3
Affiliations
  • 1. Department of Radiology, Women and Children's Hospital of Chongqing Medical University, 400016 Chongqing, PR China; State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, 400016 Chongqing, PR China.
  • 2. Department of Radiology, Women and Children's Hospital of Chongqing Medical University, 400016 Chongqing, PR China.
  • 3. Department of Radiology, Women and Children's Hospital of Chongqing Medical University, 400016 Chongqing, PR China; State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, 400016 Chongqing, PR China. Electronic address: [email protected].
PMID: 41518922 DOI: 10.1016/j.jcis.2026.139847
Abstract

Limited antigen presentation renders high-intensity focused ultrasound (HIFU)-triggered immune response insufficient to improve prognosis. Herein, manganese-based metal-organic frameworks (termed AMS MOFs) were designed to co-deliver hypoxia-activated prodrug banoxantrone (AQ4N) and stimulator of interferon genes (STING) agonist SR-717, for enhancing antigen presentation-related postoperative immunotherapy. Under hypoxic microenvironment after HIFU surgery, the released AQ4N initiated immunogenic cell death causing the release of danger-associated molecular patterns. Simultaneously, SR-717 activated STING pathway and together with Mn2+-promoted the binding affinity of cGAMP-STING, finally eliciting robust type I interferon response. The synergism of these processes consequently promoted immune responses relevant to tumor antigen presentation and inhibited breast tumor recurrence and metastasis. This study presents a strategy for improving the overall prognosis of all surgery including HIFU.

Keywords
Antigens cross-presentation; Breast cancer; HIFU; Immunotherapy; MOFs.
Products